| ID | Sequence | Length | GC content |
|---|---|---|---|
| IFNG-AS1:1 | CCUUGCCCACCUUCUGCACACCAAGCGUGGAUUCUGCAAAACGUGAGCC… | 1131 nt | 0.3731 |
| IFNG-AS1:2 | CUGCAAUUUCAGGUAGCUUUUCUGACUCUUAAAGAGAUCUCAAGUAUAC… | 1791 nt | 0.3914 |
| IFNG-AS1:3 | CUGCAAUUUCAGGUAGCUUUUCUGACUCUUAAAGAGAUCUCAAGUAUAC… | 1909 nt | 0.3913 |
| IFNG-AS1:4 | GGUAGCUUUUCUGACUCUUAAAGAGAUCUCAAGUAUACCUUCAGAGAAA… | 902 nt | 0.4169 |
| IFNG-AS1:5 | GGGAAGGAAUAAGCCUGGAAGAAAAAGAUACAACGAACUAGCACAACGA… | 494 nt | 0.4312 |
| IFNG-AS1:6 | CGUAAAACGCUGGAGGAGAAGUCAGUAGCAAGCAGCUAAGACAACAUGG… | 1833 nt | 0.3606 |
No relevant information is available at the moment.
A study in humans identified the IFNG-AS1 as a long non-coding RNA that is downregulated in heart failure compared to myocardial fibrosis in blood samples from patients, with its expression analyzed via RNA sequencing and validated by qPCR [Wang et al. DOI:10.3389/fcvm.2021.664044].